Title : Immune Check point Inhibitor(ICI) in Colorectal Ca(CRC)
Abstract:
CRC are among the common cancers all over the world both in incidence and as a cause of death. A form of genomic instability, occurs through the insertion or deletion of repeating nucleotides during DNA replication and failure of the mismatch repair system to correct errors in nucleotide repeat markers, patients with functional MMR mechanisms are MSS or pMMR. About 8-10 % of all CRCs have dMMR activity this is due to inactivating “events” to one of several DNA MMR genes MSH2 and MLH1 (the“major” DNA MMR genes ) MSH6 and PMS2 (the “minor” DNA MMR genes) dMMR) Will present a cohort of patient with dMMR with highlight on response rate and survival supported by clincal response and images and lab test.
Audience Take Away:
- This data provides the framework for immuno- therapy in CRC
- Highlights the clinical impact of biomarker driven therapy in CRC
- The tumor agnostic mismatch repair deficiency population of CRC has the potential eliminate the need for chemotherapy, radiation and surgery
